Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, Bioscan to Co-Market Imaging Instruments, Software

NEW YORK (GenomeWeb News) – Definiens and Bioscan have signed an agreement to co-market Bioscan’s instruments for noninvasive in vivo animal imaging with Definiens’ image analysis software, the companies said today.
Bioscan, based in Morristown, NJ, and Definiens, based in Munich, Germany, said they have agreed to “conduct cooperative marketing activities and host joint workshops and events” that will offer customers integrated training and implementation programs.
The firms said they will “continue to explore further opportunities for cooperation,” which could include the co-development of user interfaces to incorporate Definiens’ software into Bioscan’s hardware.
Existing Bioscan customers will also receive “introductory offers” for Definiens applications, the partners said.
Bioscan offers the NanoSPECT/CT and NanoPET/CT in vivo animal imaging systems, which analyze molecular function at the nanoliter scale.
Definiens’ Cognition Network Technology software is used for analyzing image data from a range of platforms, including cell and tissue-based assays and in vivo imaging systems.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.